SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending downwards as investors react to earnings results and future outlook, with concerns focused on debt and increased spending related to AI infrastructure. The community is debating whether the company's AI investments will translate to profits, with some expressing skepticism about the current valuation. Others believe the selloff is an overreaction and a buying opportunity, pointing to Oracle's backlog and potential for long-term growth.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards as the community discusses its potential acquisition of Warner Bros. Discovery and the impact of increased debt. Some traders believe the stock is oversold and poised for a bounce, while others anticipate further declines depending on the outcome of the bidding war with Paramount and potential regulatory hurdles.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

MSFT is trending amid mixed sentiment, with some traders expressing frustration over its recent performance relative to the broader market and other tech stocks; many believe the stock is being manipulated. Despite the negative sentiment, there's optimism regarding Microsoft's AI initiatives and potential upside, with analysts reiterating buy ratings and high price targets.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as traders discuss its bullish chart structure and potential breakout, fueled by strong buying momentum. Community members are highlighting confidence in the stock's trend and anticipating further upward movement. Some traders point to the company's need for cash and recent news including an acquisition that could affect the company.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

Mawson Infrastructure Group ($MIGI) is trending due to sector-wide strength in Bitcoin mining stocks and speculation around its expanding digital infrastructure, including AI/GPU hosting. The community is discussing the stock's low float, potential for a short squeeze, and anticipation of catalysts from an upcoming Emerging Growth Conference. Some traders are setting aggressive price targets, citing the company's infrastructure buildout and potential for new contracts.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana's stock is trending amid discussions about its upcoming inclusion in the S&P 500, with some traders anticipating a continued rise while others foresee a sell-the-news event. Community members are debating the company's valuation, debt, and potential risks, with a segment highlighting possible fraud and regulatory concerns. Bullish sentiment is fueled by the S&P 500 inclusion, while bears point to the high P/E ratio and subprime loan book.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to its high volatility and potential for sharp scalps, though a confirmed catalyst remains unclear. Community discussions revolve around whether it can repeat the massive gains seen earlier in the day, or if it is set to fade, drawing comparisons to similar volatile runners like $SMX. Traders are actively debating strategies around potential overnight moves and short positions.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as precious metals gain momentum, with silver outperforming gold and reaching historic highs, sparking discussions about industrial demand and a potential shift in the metals landscape. Community members are weighing the impact of possible Fed rate cuts and a weakening dollar, while anticipating a continued surge in precious metal prices. Some traders suggest caution and profit protection before year-end.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to new highs, driven by industrial demand and a potential supply squeeze. Community discussions focus on the possibility of further gains and the impact of potential market manipulation, while some analysts warn of overbought conditions and an impending correction. Broader trends, such as central bank policy and a weaker dollar, are also being considered as potential catalysts for continued upward momentum.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals is trending due to increased momentum in low-float biotech stocks, with traders actively discussing its potential for a significant price surge. The community is also highlighting the company's phase 3 trial and analyzing the stock's chart patterns, while noting the company's small market cap relative to the potential market for its lead drug candidate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Systematic Financial Management LP Increases Holdings in OraSure Technologies, Inc. $OSUR

Systematic Financial Management LP grew its position in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 35.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The...

Private Management Group Inc. Has $16.38 Million Holdings in OraSure Technologies, Inc. $OSUR

Private Management Group Inc. grew its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 23.6% in the 2nd quarter, according to the company in its most recent Form 13F...

Stephens Lowers OraSure Technologies (NASDAQ:OSUR) Price Target to $3.00

Stephens lowered their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an "equal weight" rating on the stock in a research note on Wednesday...

Acadian Asset Management LLC Lowers Position in OraSure Technologies, Inc. $OSUR

Acadian Asset Management LLC lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 20.4% during the second quarter, according to the company in its most recent...

OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results

OraSure Technologies (NASDAQ:OSUR - Get Free Report) issued its earnings results on Wednesday. The medical instruments supplier reported ($0.17) EPS for the quarter, missing the consensus estimate of...

OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of +18.75% and -7.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

InfuSystems Holdings, Inc. (INFU) Tops Q3 Earnings Estimates

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of +37.50% and -1.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Tilray Brands, Inc. (TLRY) Reports Break-Even Earnings for Q1

Tilray Brands (TLRY) delivered earnings and revenue surprises of +100.00% and +1.29%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Altai Capital Management is reportedly preparing to launch a board fight at medical device company OraSure Technologies (OSUR).The hedge fund is one of the biggest owners of OraSure and built up its stake from 3% at the end of June to 5% in recent weeks, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/transactional/altai-capital-lays-groundwork-board-fight-orasure-technologies-sources-say-2025-09-09/">reported</a>, citing two people familiar with the matter.The larger stake allows Altai to press its case for board representation more forcefully, the people told Reuters. Two OraSure directors will stand for reelection at next year's annual meeting, and Altai is likely to nominate two candidates, including its founder, Rishi Bajaj, at some point, the report stated. Bajaj last year suggested that an investor with experience in capital allocation should join the OraSure board, the sources told Reuters.Shares of the company traded 2% higher at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/OSUR">OSUR stock</a> remained in ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_44_48_PM_png_7a065a0f80.webp" alt="OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes it’s ‘good news’.<stembedurl>https://stocktwits.com/Gantz7/message/627948069</stembedurl>However, another user cheered for the Altai founder.<stembedurl>https://stocktwits.com/AnonMav/message/627979684</stembedurl>Last month, Reuters reported that OraSure Technologies (OSUR) received a letter from healthcare entrepreneur Ron Zwanziger stating that he may pursue a more "adversarial path" if the board continues to resist his offer to buy the company.Zwanziger made an unsolicited all-cash offer to buy OraSure for between $3.50 and $4.00 a share in June but was rebuffed. The entrepreneur stated in his letter that other investors have grown concerned and reached out to him."If the board is not willing to entertain a collaborative discourse, we will be left with no choice but to consider all alternatives available," the letter <a href="https://stocktwits.com/news-articles/markets/equity/orasure-receives-warning-from-ron-zwanziger/chssxJ9RdS9">said</a>, without detailing the alternative options. "We would prefer to work together with you in a collaborative fashion to realize the full value potential for all shareholders, rather than pursuing a more adversarial path," the letter stated, as per the report. However, Altai and Zwanziger are not working together, Reuters said on Tuesday.For the three months through the end of June, OraSure’s total net revenues fell 43% year-on-year to $31.24 million, while diluted and adjusted loss per share stood at $0.19 compared to a profit of $0.08 in the corresponding quarter of 2024.OSUR stock is down 8% this year and approximately 21% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  

Equity

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  


Medical device company OraSure Technologies (OSUR) received a letter from healthcare entrepreneur Ron Zwanziger on Monday stating that he may pursue a more "adversarial path" if the board continues to resist his offer to buy the company, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/healthcare-entrepreneurs-letter-threatens-adversarial-path-after-orasure-tech-2025-08-25/">reported</a> on Monday.Zwanziger made an unsolicited all-cash offer for the company earlier in the summer but was rebuffed. The entrepreneur stated in his letter that other investors have grown concerned and reached out to him, as per the report."If the board is not willing to entertain a collaborative discourse, we will be left with no choice but to consider all alternatives available," the letter said, without detailing the alternative options. "We would prefer to work together with you in a collaborative fashion to realize the full value potential for all shareholders, rather than pursuing a more adversarial path," the letter read, as per the report.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OSUR">OSUR stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_2_07_26_PM_png_4f028f580f.webp" alt="OSUR's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>OSUR's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>Zwanziger submitted a proposal to buy OraSure for between $3.50 and $4.00 a share in June, the report said. The stock currently trades below these levels. "As time passes without any productive engagement between ourselves, not only do your cash reserves and share price decline, but our offer price may be lowered or withdrawn," the letter said.The entrepreneur also highlighted in his letter that the company’s second-quarter revenue dropped, and its share repurchase program in March ‘failed’ to boost its share price, the report said.For the three months through the end of June, the firm’s total net revenues fell 43% year-on-year to $31.24 million, while diluted and adjusted loss per share stood at $0.19 compared to a profit of $0.08 in the corresponding quarter of 2024. &nbsp;OSUR stock is down by 12% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/valneva-stock-tumbles-after-us-fda-suspension-of-ixchiq-license/chssvsiRdSe">Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

OraSure Receives Warning From Ron Zwanziger: Entrepreneur Warns Of Adversarial Path If Board Continues To Refuse Buyout Offer

Zwanziger made an unsolicited all-cash offer for the company earlier in the summer but was rebuffed.

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

Orasure Technologies Inc.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

OSUR
Orasure Technologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OSUR News

OSUROrasure Technologies Inc.